Garde Capital’s Sarepta Therapeutics SRPT Stock Holding History

Garde Capital’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,085	Closed	-$140K	–	284
2024 Q1	$140K	Buy	+1,085	New	+$133K	0.01%	244

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Garde Capital's SRPT Position: Q2 2024 in Review

Garde Capital sold out of Sarepta Therapeutics (SRPT) in Q2 2024, closing a stake of 1,085 shares — an estimated $140K sold.

Garde Capital first reported a position in SRPT in Q1 2024 and held it in 1 quarter. The position peaked at $140K in Q1 2024. 483 funds tracked by Wall St. Rank hold SRPT as of Q2 2024.

Garde Capital reported no remaining Sarepta Therapeutics position as of Q2 2024 after selling out during the quarter.
Garde Capital sold 1,085 Sarepta Therapeutics shares in Q2 2024, an estimated $140K.
Garde Capital first reported a position in Sarepta Therapeutics in Q1 2024 and held it in 1 quarter.
Garde Capital's Sarepta Therapeutics position peaked at $140K in Q1 2024.
483 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2024.

Based on Garde Capital's 13F filing for Q2 2024, filed 19 Aug 2024.